235 related articles for article (PubMed ID: 8721923)
1. [Daily defined doses of parkinsonian drugs in Alcoi].
Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
[TBL] [Abstract][Full Text] [Related]
2. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Mizuno Y; Kondo T; Takubo H; Yokochi F
No To Shinkei; 1996 May; 48(5):467-72. PubMed ID: 8672306
[TBL] [Abstract][Full Text] [Related]
3. [The evolution of use of anti-Parkinson drugs in Spain].
Montané E; Vallano Ferraz A; Castel JM
Rev Neurol; 2002 Apr 1-15; 34(7):612-7. PubMed ID: 12080509
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
5. [The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs].
Artázcoz Sanz MT; Viñes Rueda JJ
Rev Esp Salud Publica; 1995; 69(6):479-85. PubMed ID: 8789360
[TBL] [Abstract][Full Text] [Related]
6. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
8. Controversies in the therapy of Parkinson's disease.
Fahn S
Adv Neurol; 1996; 69():477-86. PubMed ID: 8615168
[TBL] [Abstract][Full Text] [Related]
9. [Initiation of treatment in Parkinson disease].
Ghika J
Praxis (Bern 1994); 1995 Sep; 84(38):1018-20. PubMed ID: 7481298
[TBL] [Abstract][Full Text] [Related]
10. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Mizuno Y; Kondo T; Takubo H; Yokochi F
No To Shinkei; 1994 May; 46(5):465-71. PubMed ID: 8060685
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
12. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
13. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Parkinson's disease.
Bergus G
J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
[No Abstract] [Full Text] [Related]
15. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
Fischer PA
J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
[TBL] [Abstract][Full Text] [Related]
17. (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.
Knoll J
Biomed Pharmacother; 1996; 50(6-7):315-7. PubMed ID: 8952875
[No Abstract] [Full Text] [Related]
18. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
[No Abstract] [Full Text] [Related]
20. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs].
Martínez-Suárez MM; Blázquez-Menes B
Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
